🔗 Permalink

Inventor profile of:

James H. LEE

City:

Devon, Pennsylvania

Country:

United States

Published Applications:

Last publication date:

2013-08-15

Top Assignees for applications by James H. LEE

The entities that hold a legal rights for patent applications filed by inventor LEE James H.:

Medicis Pharmaceutical Corporation 7 Scottsdale, AZ United States
Graceway Pharmaceuticals. LLC 7 Bristol, TN United States
Medicis Pharmaceutical Corporation 1 Bridgewater, NJ United States
Medicis Pharmaceutical Corporation 1 Scottsdae, AZ United States

Recent patent applications by LEE James H.

James H. LEE from Devon, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2013-08-15

US20130210855A1

Human necessities

2×2×2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75 % imiquimod

#2 | 2012-12-27

US20120329825A1

Human necessities

LOWER DOSAGE STRENGTH IMIQUIMOD FORMULATIONS AND SHORT DOSING REGIMENS FOR TREATING GENITAL AND PERIANAL WARTS

#3 | 2012-12-27

US20120329824A1

Human necessities

LOWER DOSAGE STRENGTH IMIQUIMOD FORMULATIONS AND SHORT DOSING REGIMENS FOR TREATING GENITAL AND PERIANAL WARTS

#4 | 2012-12-27

US20120329823A1

Human necessities

LOWER DOSAGE STRENGTH IMIQUIMOD FORMULATIONS AND SHORT DOSING REGIMENS FOR TREATING GENITAL AND PERIANAL WARTS

#5 | 2012-11-15

US20120289538A1

Human necessities

Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts

#6 | 2011-10-27

US20110263637A1

Human necessities

UP TO SIX WEEKS DOSING REGIMEN FOR TREATING ACTINIC KERATOSIS WITH PHARMACEUTICAL COMPOSITIONS FORMULATED WITH 3.75% IMIQUIMOD

#7 | 2011-10-27

US20110263636A1

Human necessities

3 x 3 x 3 WEEK DOSING REGIMEN FOR TREATING ACTINIC KERATOSIS WITH PHARMACEUTICAL COMPOSITIONS FORMULATED WITH 3.75 % IMIQUIMOD

#8 | 2011-10-27

US20110263635A1

Human necessities

Method of treating actinic keratosis with 3.75% imiquimod cream

#9 | 2011-10-27

US20110263634A1

Human necessities

LOWER DOSAGE STRENGTH PHARMACEUTICAL COMPOSITIONS FORMULATED WITH 2.5% IMIQUIMOD

#10 | 2011-10-27

US20110263633A1

Human necessities

UP TO SIX WEEKS TREATMENT REGIMEN FOR TREATING ACTINIC KERATOSES WITH PHARMACEUTICAL COMPOSITIONS FORMULATED WITH 2.5% IMIQUIMOD

#11 | 2011-10-20

US20110257219A1

Human necessities

LOWER DOSAGE STRENGTH PHARMACEUTICAL COMPOSITIONS FORUMLATED WITH 3.75% IMIQUIMOD

#12 | 2011-10-20

US20110257218A1

Human necessities

2×2×2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75 % imiquimod

#13 | 2011-10-20

US20110257217A1

Human necessities

3 x 3 x 3 WEEK TREATMENT REGIMEN FOR TREATING ACTINIC KERATOSIS WITH PHARMACEUTICAL COMPOSITIONS FORMULATED WITH 2.5% IMIQUIMOD

#14 | 2011-10-20

US20110257216A1

Human necessities

2×2×2 week treatment regimen for treating actinic keratosis with pharmaceutical compositions formulated with 2.5% imiquimod

#15 | 2011-08-25

US20110207766A1

Human necessities

LOWER DOSAGE STRENGTH IMIQUIMOD FORMULATIONS AND SHORT DOSING REGIMENS FOR TREATING GENITAL AND PERIANAL WARTS

#16 | 2011-01-27

US20110021555A1

Human necessities

LOWER DOSAGE STRENGTH IMIQUIMOD FORMULATIONS AND SHORTER DOSING REGIMENS FOR TREATING ACTINIC KERATOSES

#17 | 2008-11-13

US20080280943A1

Human necessities

METHODS AND PACKAGES TO ENHANCE SAFETY WHEN USING IMIQUIMOD TO TREAT CHILDREN DIAGNOSED WITH SKIN DISORDERS

InventorID:

391310 ⎘